Sign in
Taking peopleNo phase

Clinical Impact of a Multiplex Rapid Diagnostic Pneumonia Panel Testing in Critically-ill Patients With Severe Hospital-acquired Pneumonia, Ventilator-associated Pneumonia and Community-acquired Pneumonia With High Risk of Multidrug Resistant Pathogen

Key facts

Who runs it
Mahidol University
Where
Thailand2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
64 people, planned
Started
1 Feb 2025
Expected to end
1 Oct 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Pneumonia Panel by FilmArray
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients who have received complete information about the research and who have not objected to the use of its data
  • Patients with suspected pneumonia infection

Who cannot take part

  • Drug overdose
  • Active immediate life-threatening cardiac arrhythmia, defined as ventricular tachycardia and ventricular fibrillation
  • Acute cerebral vascular event, including both acute ischemic stroke or intracranial hemorrhage Acute coronary syndrome
  • Life-threatening gastrointestinal hemorrhage
  • Advanced-stage cancer with predicted survival less than 1 year
  • Cardiogenic shock

This trial is currently available in Thailand.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objective of the research is to ascertain the influence of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalised in the ICU for severe respiratory disease.

Read full original descriptionShow less

The diagnostic process for pneumonia has become significantly more intricate over the past decade due to the interference of the biological, radiological, and clinical criteria of patients hospitalised in the intensive care unit with the conventional criteria for the diagnosis of severe respiratory diseases. Additionally, patients who are hospitalised in the ICU are at a heightened risk of contracting other associated infections. Consequently, patients are frequently administered antibiotics, whether or not they are effective, as it is challenging to promptly determine the aetiology of their symptoms using conventional methods.

To enhance the diagnostic and therapeutic aspects of their treatment, we implemented a novel syndromic molecular test in our laboratories. This test is designed to expedite and enhance the management of pneumonia and the stewardship of antibiotics. This research will include 80 to 100 adult patients hospitalized in ICU between Feb 2025 and Feb 2027. It will take place within the Siriraj Hospital, Bangkok, Thailand.

The 2 groups in the trial

  • Experimental: Pneumonia panel groupTreatment being tested

    Pneumonia panel measurement and changing of antimicrobials according to the result of pneumonia panel

    Treatment: Pneumonia Panel by FilmArray

  • No Intervention: Standard of careNo study treatment, for comparison

    Standard practice

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 November 2026